Press Releases
Resolvyx Announces Management Transition Plan
BEDFORD, MA — July 20, 2009 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced a management transition plan. Gregory Weinhoff, M.D., will serve as Executive Chairman of the Resolvyx’s board of directors, and will be actively involved in directing Resolvyx’s strategy and guiding the company’s product development plans. Dr. Weinhoff has been a member of the Resolvyx board of directors since the company’s founding in 2005, and he is a partner with CHL Medical Partners. Paul Rubin, M.D., who previously served as Chief Executive Officer of Resolvyx, will step down from day-to-day management of the company but will continue to support Resolvyx’s ongoing activities in a consulting role.
As part of this transition, two members of the Resolvyx management team will take senior leadership roles in directing the company’s operating activities. James Nichols, Ph.D., formerly the executive vice president for corporate development, will become Chief Operating Officer and be responsible for corporate development, commercial development, clinical program management and business operations. Philip Vickers, Ph.D., who joined the company in April 2009 as Chief Scientific Officer and board member, will continue to be responsible for all R&D at Resolvyx.
About Resolvins
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed. Resolvins are shown to be highly potent and efficacious in preclinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.
Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn’s disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory diseases (like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer’s disease). Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.
In 2008, Resolvyx initiated the first clinical trial of a resolvin therapeutic, RX-10045, which is in a PhaseI/II trial for patients with dry eye.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of more than 55 patents and applications.
The company's headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com.